Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diseases of the Thyroid

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 23 articles: HTML format

Single Articles

April 2024
1. GREENSPAN BS, Hofman MS, Buscombe J
   The Accomplishments and Legacy of Saul Hertz, MD.
   J Nucl Med. 2024;65:659-663.
   PubMed     Abstract available
   
   
   March 2024
2. KIM KJ, Choi J, Kim KJ, Song E, et al
   Cancer Risk in Graves Disease with Radioactive (131)I Treatment: A Nationwide Cohort Study.
   J Nucl Med. 2024 Mar 28:jnumed.123.266531. doi: 10.2967/jnumed.123.266531.
   PubMed     Abstract available
   
   
   
3. GREENSPAN BS, Hofman MS, Buscombe J
   Commentary on "Radioactive Iodine: A Living History".
   J Nucl Med. 2024;65:495.
   PubMed    
   
   
   December 2023
4. VENTURA D, Dittmann M, Buther F, Schafers M, et al
   Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
   J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
   PubMed     Abstract available
   
   
   November 2023
5. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
   Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
   J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
   PubMed     Abstract available
   
   
   
6. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
   CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
   J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
   PubMed    
   
   
   October 2023
7. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
   Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
   J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
   PubMed     Abstract available
   
   
   June 2023
8. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
   Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
   J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
   PubMed    
   
   
   April 2023
9. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
   The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
   J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
   PubMed     Abstract available
   
   
   January 2023
10. VON GUGGENBERG E, Uprimny C, Klingler M, Warwitz B, et al
    Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977.
    PubMed     Abstract available
    
    
    December 2022
11. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    PubMed     Abstract available
    
    
    November 2022
12. OEVERHAUS M, Koenen J, Bechrakis N, Stohr M, et al
    Radioiodine ablation of thyroid remnants in patients with Graves' orbitopathy.
    J Nucl Med. 2022 Nov 23:jnumed.122.264660. doi: 10.2967/jnumed.122.264660.
    PubMed     Abstract available
    
    
    June 2022
13. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    
    
    
    February 2022
14. SIGNORE A, Campagna G, Marinaccio J, de Vitis M, et al
    Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with rhTSH for remnant ablation.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263442. doi: 10.2967/jnumed.121.263442.
    PubMed     Abstract available
    
    
    August 2021
15. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    PubMed     Abstract available
    
    
    July 2021
16. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available
    
    
    
17. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available
    
    
    March 2021
18. SEIFERT R, Schafers MA, Heitplatz B, Kerschke L, et al
    Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.
    J Nucl Med. 2021 Mar 26. pii: jnumed.121.261898. doi: 10.2967/jnumed.121.261898.
    PubMed     Abstract available
    
    
    February 2021
19. MARIANI G, Tonaccehra M, Grosso M, Fiore E, et al
    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis.
    J Nucl Med. 2021 Feb 12. pii: jnumed.120.251504. doi: 10.2967/jnumed.120.251504.
    PubMed     Abstract available
    
    
    
20. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Ansquer C, et al
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.252791. doi: 10.2967/jnumed.120.252791.
    PubMed     Abstract available
    
    
    October 2020
21. MARIANI G, Tonacchera M, Grosso M, Orsolini F, et al
    The role of nuclear medicine in the clinical management of benign thyroid disorders. Part 1. Hyperthyroidism.
    J Nucl Med. 2020 Oct 2. pii: jnumed.120.243170. doi: 10.2967/jnumed.120.243170.
    PubMed     Abstract available
    
    
    July 2020
22. GRIMALDI S, Lagarde S, Harle JR, Boucraut J, et al
    Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies.
    J Nucl Med. 2020 Jul 24. pii: jnumed.120.249292. doi: 10.2967/jnumed.120.249292.
    PubMed     Abstract available
    
    
    March 2020
23. WU D, Gomes Lima CJ, Bloom G, Burman KD, et al
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After (131)I Therapy for Thyroid Cancer.
    J Nucl Med. 2020;61:397-404.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.